Biocon Limited shareholders have approved ten resolutions through a postal ballot process, including the revision of remuneration for Executive Chairperson Kiran Mazumdar-Shaw and the appointment of Shreehas Pradeep Tambe as Chief Executive Officer & Managing Director. The voting, conducted via remote e-voting from May 09 to June 07, 2026, also sanctioned the issuance of equity shares on a preferential basis and the appointment of several independent directors. All resolutions received the requisite majority and were deemed passed on June 07, 2026.

The postal ballot notice was sent to members whose names appeared on the register of members as of the cut-off date of May 01, 2026. The company provided a 30-day window for e-voting, commencing on May 09, 2026. A corrigendum to the notice was issued on May 29, 2026, to provide clarifications regarding the preferential issue of equity shares, following advice from the stock exchanges. Shareholders were given the option to modify their votes prior to the deadline, though no such requests were received.

Voting Results

The scrutinizer's report confirmed that 73.56% of the total paid-up equity capital participated in the e-voting process. The resolutions passed with varying degrees of support, with the preferential issue of shares receiving near-unanimous approval at 99.99% of valid votes.

Key Appointments

The approvals pave the way for significant changes in the company's leadership and board composition. Shreehas Pradeep Tambe is set to take over as Chief Executive Officer & Managing Director. The board will also see the induction of five new independent directors: Rajiv Malik, Daniel Bradbury, Peter Baron Piot, Arun Suresh Chandavarkar, and Nivruti Rai. Additionally, Thomas Jason Roberts was appointed as a Non-Executive Non-Independent Director, and Rekha Mehrotra Menon was re-appointed as an Independent Director.

The scrutinizer, Pradeep Bheemsen Kulkarni of V Sreedharan & Associates, verified the e-voting process and confirmed that the results were declared based on the votes cast up to 5:00 PM on June 07, 2026. The report was submitted to the company on June 08, 2026.

Biocon Limited has significantly improved its financial leverage, reducing its net debt to EBITDA ratio by approximately 1.6x. This improvement was driven by a systemic debt reduction plan and enhanced EBITDA performance. The company disclosed these developments in an investor presentation scheduled for analyst and institutional investor meets on June 02, 2026, and June 08, 2026.

The company completed an acquisition refinancing initiative that has strengthened its balance sheet and improved debt maturity profiles. Under the original debt profile as of September 2024, Biocon Biologics faced total debt obligations of $1,389 million, comprising acquisition debt, bilateral debt, and working capital. The refinancing has restructured these obligations into a new profile totaling $1,348 million as of March 2026, which includes an $800 million senior secured bond and new facility or bilateral debt.

Debt Maturity Schedule

The refinancing strategy has deferred major debt maturities, providing increased liquidity to address business needs. The new schedule shifts significant repayments to later fiscal years, allowing the company flexibility to invest cash from operations back into the business.

The original amortization schedule had required substantial repayments starting in FY25, whereas the new structure pushes the largest maturities toward FY28 and FY29. The total debt under the new arrangement stands at $1,348 million, compared to the previous $1,389 million.

Strategic Integration and Stake Acquisition

Biocon has advanced its business consolidation strategy, increasing its stake in Biocon Biologics to 99.2%. The Board of Directors has granted in-principle approval to acquire the remaining 0.8% stake. This integration combines the generics and biosimilar businesses to unlock value for patients, prescribers, customers, and shareholders.

The company reported that major investments in capacities and infrastructure are largely complete across the Biocon Group. This development positions the entity to meet demand requirements for the next five years or more. The consolidated business is positioned among global leaders in biosimilars and complex generics, with a portfolio addressing a total market opportunity of over $200 billion.

Financial Performance

The investor presentation highlighted robust financials for the Biocon Group, noting that new launches and business consolidation are expected to improve operating margins. The company has a vertically integrated operational model with research and development, manufacturing, and commercialization capabilities spanning 120+ countries. It holds 215+ cGMP approvals from 25+ regulators, including the US FDA and EMA.